The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure

Hobart, Jeremy; Lamping, Donna L.; Fitzpatrick, Ray; Riazi, Afsane; Thompson, Alan J.

doi:10.1093/brain/124.5.962

Cited by 947 publications

(855 citation statements)

References 31 publications

Supporting

Mentioning

807

Contrasting

Unclassified

Order By: Relevance

“…The fact that mean scores on the Energy and Cognitive/Mental subscales differed significantly by PDDS group but not by MS disease classification may be due to the purposes of the respective categorization methods. The PDDS largely measures mobility function, 11 rather than disease course. Although there is not 100% agreement among MS clinicians regarding the…”

Section: Resultsmentioning

confidence: 99%

“…It also promotes shared decision-making (MSQOL-54), 8 the Multiple Sclerosis Quality of Life Inventory (MSQLI), 9 the Functional Assessment of Multiple Sclerosis (FAMS) quality of life instrument, 10 and the Multiple Sclerosis Impact Scale (MSIS-29). 11 All of these measures include assessment of physical and psychological conditions, common MS symptoms, energy/fatigue, and social relationships. Cognition and sexual functioning are also included in the MSQOL-54, MSQLI, and FAMS.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Monitoring My Multiple Sclerosis

Gulick¹,

Namey²,

Halper³

2011

International Journal of MS Care

View full text Add to dashboard Cite

Optimal health of people with multiple sclerosis (MS) can be promoted by patients' sharing of health information gained through periodic self-monitoring with their health-care providers. The purpose of this study was to develop a valid and reliable self-administered scale to obtain information about MS patients' health status and the impact of the disease on their daily lives. We named this scale "Monitoring My Multiple Sclerosis" (MMMS) Analysis of variance demonstrated that the total scale and the Physical subscale, but not the Relationships subscale, showed significantly worse functioning for patients with either moderate or severe disability as measured by the PDDS than for patients with mild disability (P < .001). The Cognitive/Mental subscale showed significantly worse functioning for patients with moderate disability than for patients with mild disability (P < .05). However, the Energy subscale showed significantly worse functioning among moderately disabled patients than among severely disabled patients (P < .01). Independent t tests demonstrated that patients classified as having secondary progressive multiple sclerosis had significantly worse scores on the total MMMS (P < .05) and the Physical subscale (P < .001) than those classified as having relapsing-remitting multiple sclerosis. The MMMS demonstrated satisfactory reliability and validity and is recommended for use by MS patients and their health-care providers as a mechanism to promote the sharing of health information, to the benefit of both patients and providers. Int J MS Care. 2011;13:137-145.. Multiple sclerosis (MS) is a chronic and progressive inflammatory autoimmune disease of the central nervous system (CNS), with onset usually occurring during young adulthood. 1 The disease is initially characterized by relapsing-remitting symptoms in most patients and may later take a progressive course. 2,3 The symptoms and signs of MS reflect the CNS area of neural impairment. 1 Neural impairment in the cerebrum affects cognition; cerebellum impairment affects balance and produces tremors; brainstem impairment is associated with diplopia, vertigo, and impaired speech and swallowing; and spinal cord impairment causes weakness, stiffness, painful spasms, bladder dysfunction, sexual dysfunction, and constipation. These symptoms are reflected in accumulating disabilities experienced by the person with MS that affect physical, social, and cognitive/mental functioning.Currently there is no cure for MS, although there are many partially effective treatments and interventions that focus on symptom management. Because of the great variability in symptoms and disabling conditions experienced by MS patients, ongoing monitoring of physical, social, and cognitive/mental functioning is important to determine both appropriate counseling and treatment and the effectiveness of such interventions. Self-monitoring by MS patients who then share health-related information with their health-care providers holds promise for controlling or alleviating symptoms, resulting in ...

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Monitoring My Multiple Sclerosis

Gulick¹,

Namey²,

Halper³

2011

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…Quality of life, such as the MS Quality of Life Inventory (LaRocca et al, 1996), the MS Impact Scale (Hobart, Lamping, Fitzpatrick, Riazi, & Thompson, 2001), the Short Form-36 (SF-36; Ware & Kosinski, 2001), the Euro-QoL (Brooks, 1996). .…”

Section: Types Of Outcomesmentioning

confidence: 99%

External memory aids for memory problems in people with multiple sclerosis: A systematic review

Goodwin

Lincoln

Nair

et al. 2015

Neuropsychological Rehabilitation

View full text Add to dashboard Cite

Approximately 40-60% of people with multiple sclerosis (MS) have memory problems, which adversely impact on their everyday functioning. Evidence supports the use of external memory aids in people with stroke and brain injury, and suggests they may reduce everyday memory problems in people with MS. Previous reviews of people with MS have only evaluated randomised trials; therefore this review included other methodologies. The aim was to assess the efficacy of external memory aids for people with MS for improving memory functioning, mood, quality of life, and coping strategies. Seven databases were systematically searched. Intervention studies that involved training in the use of external memory aids, e.g., personal digital assistants, with at least 75% of people with MS, were included. Based on study design, quality was rated with the SCED or PEDro scale. Nine studies involving 540 participants were included. One single case experimental design (mean of 8 on SCED scale) and eight group studies (mean of 5 on PEDro scale) were included. One study reported a significant treatment effect on subjective memory functioning, two on mood, and two on coping strategies. There is insufficient evidence to support or refute the effectiveness of external memory aids for improving memory function in people with MS.

show abstract

“…Объем очагов не оценивал-ся, поскольку активность на МРТ измерялась (со-гласно единому протоколу) в соответствии с ло-кальными клиническими стандартами, а не неза-висимыми специалистами централизованно. Вли-яние терапии натализумабом на качество жизни оценивалось с помощью состоящей из 36 вопросов сокращенной формы оценки состояния здоровья (SF-36) [49][50][51], а также с помощью состоящей из 29 пунктов шкалы функциональных последствий рассеянного склероза (MSIS-29 -Multiple Sclerosis Impact Scale) [52].…”

Section: материал и методыunclassified